https://africanjournalofbiomedicalresearch.com/index.php/AJBR
Afr. J. Biomed. Res. Vol. 28(2s) (February 2025); 01-10
Research Article

Biomarkers For Thyroid Dysfunction In Diabetes: New Insights And Future Directions

Salini A B[1*], Subhashini V[2], Minu K P[3]

[1*]Department of Pharmacy Practice, Triveni Institute of Pharmacy, Thrissur, Kerala,India
salini.babysalini@gmail.com

[2] Department of Pharmacology, Vels Institute of Science, Technology & Advanced Studies, Pallavaram, Chennai, Tamil Nadu, India. subhavedagiri@hotmail.com

[3] Department of Pharmacology, MGM College of pharmaceuticals sciences, Valiyaparambu, Edayur.P.O, Valanchery, Kerala, India. minukpushpan@gmail.com.

Abstract
Thyroid dysfunction and diabetes mellitus are two closely related metabolic health conditions. The bidirectional relationship between these disorders emphasizes the need to elucidate their common pathophysiology and to identify biomarkers for early diagnosis and treatment. This review summarizes recent advances in biomarker identification for thyroid dysfunction in diabetic populations, describes its clinical application, and maps out future directions in research and therapeutics. A review of literature from 2014 to 2024 was performed, including studies that investigated the conventional and emerging biomarkers for thyroid dysfunction in diabetes. The analysis also includes the incorporation of artificial intelligence (AI) in biomarker discovery and advancement in analytical techniques. Although conventional biomarkers such as TSH, free T3, and free T4 are still important in determining thyroid dysfunction, they are confounded by glycemic control, comorbidities, and polypharmacy. Additional diagnostic precision is provided by emerging biomarkers, including reverse T3, cytokines, and genetic markers. With highly sensitive assays and omics technology together with artificial intelligence and big data analytics, novel biomarker discovery can be achieved, and personalized medicine approaches made feasible.
The integration of advanced biomarker research with novel technologies may provide a means to improve the diagnostic accuracy and therapeutic strategy for thyroid dysfunction in diabetes. Future studies should focus on validating new biomarkers, understanding molecular pathways using AI for predictive modeling, and developing individualized treatment.

Keywords: Thyroid dysfunction, diabetes mellitus, biomarkers, personalized medicine, artificial intelligence

***Author Correspondence email:** salini.babysalini@gmail.com*

Received: Accepted:

DOI: https://doi.org/10.53555/AJBR.v28i2S.6649

1. Introduction

Thyroid dysfunction is a spectrum of disorders including hypothyroidism and hyperthyroidism defined by abnormal levels of thyroid hormones. They are important hormones regulating metabolism, growth, and development. Thyroid dysfunction and diabetes mellitus occur simultaneously, and each is associated with altering the clinical course of the other. The prevalence of thyroid disorders is higher in diabetic individuals than in the general population, as shown by

studies of the epidemiology. Patients with type 1 diabetes have an increased prevalence of autoimmune thyroid disorders, especially in women, because of shared genetic susceptibilities to the two autoimmune conditions (Frommer *et al*., 2021). The relationship is more complex in type 2 diabetes. In about 30% of poorly controlled type 2 diabetic patients, abnormal serum Thyroid Stimulating Hormone (TSH) concentrations were noted. Improvement of glycemic control often resulted in the normalization of TSH levels in those with low or high TSH levels (Kalra *et al*., 2019).

The several effects of thyroid hormones, especially triiodothyronine (T3) and thyroxine (T4) are important for normal glucose metabolism. T3 increases hepatic glucose production by inducing gluconeogenesis and glycogenolysis in the liver. Genes controlled by it are implicated in several pathways, including phosphoenolpyruvate carboxykinase (PEPCK), an enzyme that limits the rate of gluconeogenesis. Hepatic glucose production is increased in hyperthyroid states contributing to hyperglycemia (Al-Bayat *et al*., 2021). The thyroid hormones also play an important role in pancreatic islet cell development and function. T3 is required for the transition of islets to glucose-responsive insulin-secreting cells (Chen *et al.,* 2018). Though hyperthyroidism impairs glucose stimulated insulin release, glucose utilization and oxidation are increased. Anti-apoptotic effects of physiological T3 treatment have been shown to prevent streptozotocin-induced islet deterioration and maintain islet structure and size (Brawerman *et al.,* 2019). T3 also increases glucose transporter 4 (GLUT4) transport to skeletal muscle and adipose tissue plasma membrane, glucose uptake and glucose tolerance. This also is associated with improved glucose tolerance and a higher degree of insulin sensitivity (Cicatiello *et al.,* 2018). The bidirectional relationship between thyroid function and glucose metabolism suggests that alterations in thyroid hormone levels will disrupt glucose homeostasis and that changes in glucose metabolism will affect thyroid function. For example, peripheral insulin resistance due to a reduced glucose uptake is linked to hypothyroidism, and hyperthyroidism increases glycemia due to increased liver glucose production (Teixeira *et al.,* 2020).

Due to the complex association between thyroid dysfunction and diabetes, there is a demand to discover biomarkers to promote early detection, enhance diagnostic accuracy, and also direct the therapy for thyroid dysfunction in diabetic patients. This review delves into the pathophysiological mechanisms linking thyroid dysfunction and diabetes, focusing on the bidirectional modulation between thyroid hormones and glucose metabolism. It evaluates the utility and limitations of conventional biomarkers like TSH, free T3, and free T4 in diagnosing thyroid dysfunction in diabetic populations while exploring emerging biomarkers, including thyroglobulin, thyroid peroxidase antibodies, reverse T3, cytokines, and genetic markers. The review highlights diagnostic challenges, the impact of glycemic control, and advances in analytical techniques like high-sensitivity assays and omics technologies. It also emphasizes clinical implications, biomarker-guided therapies, personalized medicine, and future research directions, including AI-driven biomarker discovery.

2. Pathophysiology of Thyroid Dysfunction in Diabetes

2.1. Mechanisms Linking Diabetes and Thyroid Dysfunction

The interplay of diabetes and thyroid dysfunction is a complex pathophysiological process with intricate biochemical and molecular mechanisms. There is a bidirectional relationship between diabetes and thyroid disease, in that thyroid hormones influence glucose metabolism and insulin sensitivity, and diabetes affects thyroid function through metabolic and vascular changes. (Biondi *et al.,* 2019). Autoimmune mechanisms are predominant in individuals with type 1 diabetes. Often “thyroglobulin antibodies (TG-Ab) and thyroid peroxidase antibodies (TPO-Ab)” are seen which are indicative of autoimmune thyroid disorders like Hashimoto’s thyroiditis, and Graves’ disease (Sakr *et al.,* 2020). The basis for this autoimmune overlap is shared genetic susceptibility loci, including the HLA-DR3 and CTLA-4 genes that predispose people to both diseases (Tomer *et al.,* 2014). Thyroid dysfunction is usually secondary to insulin resistance and metabolic dysregulation in type 2 diabetes (Kim *et al.,* 2022). Insulin resistance causes chronic hyperglycemia and leads to an alteration of the hypothalamic-pituitary-thyroid (HPT) axis(Yang *et al.,* 2023). Chronic hyperglycemia increases the activity of the deiodinase enzymes, especially type 3 deiodinase (D3) degrading active thyroid hormones (T3 and T4) to inactive reverse T3 (rT3). This is a shift with the development of functional hypothyroidism, reduced metabolic activity, and impaired glucose utilization (Sabatino *et al.,* 2021).

2.2. Impact of Insulin Resistance and Autoimmunity

Insulin resistance, a characteristic of type 2 diabetes, interferes with the cellular function of thyroid hormones. The thyroid is directly affected by insulin, which is a growth-promoting hormone, that directly stimulates thyroid cells to produce thyroid hormone. Reduced efficacy of insulin in insulin-resistant states leads to compensatory hyperinsulinemia, which increases the activity of the thyroid gland and may cause subclinical hypothyroidism or form goiter (Yang *et al.,*2023). Obese individuals show this phenomenon more clearly, and elevated leptin levels further modulate thyroid function by acting on the HPT axis (Walczak *et al.,* 2021). Type 1 diabetes also plays a critical role in autoimmunity. Similar processes of destruction of pancreatic β-cells by autoimmune mechanisms are paralleled by such a process in thyroid follicular cells. In both conditions, proinflammatory cytokines, such as “IL-6 and tumor necrosis factor-alpha (TNF-α)” are elevated, continuing systemic inflammation and worsening thyroid dysfunction

(Torres *et al.*, 2025). Furthermore, autoantibodies, such as TPO-Ab and TG-Ab, are not only markers of thyroid autoimmunity but also participate actively in the pathogenesis by promoting complement-mediated cytotoxicity (Fröhlich *et al.*, 2017). Oxidative stress and mitochondrial dysfunction cannot be overlooked as a role. ROS are generated in diabetes, causing mitochondrial dysfunction and damaging thyroid follicular cells. Furthermore, ROS-induced lipid peroxidation further compromises the structural integrity of thyroid cells and contributes to functional impairments (Macvanin *et al.*, 2023).

3. Current Biomarkers for Thyroid Dysfunction

The diagnosis and management of thyroid dysfunctions are dependent on some specific biomarker (TSH, free triiodothyronine, T3 or free thyroxine, T4). These biomarkers are important to evaluate thyroid gland function and to detect hypothyroidism and hyperthyroidism. These biomarkers need to be interpreted in diabetic populations with a sensitivity to the complex interaction between thyroid hormones and glucose metabolism.

3.1. Thyroid-stimulating hormone (TSH)

The most commonly used biomarker for thyroid function is TSH. The anterior pituitary gland secretes TSH, which controls the production and release of thyroid hormones. The levels are inversely related to circulating thyroid hormones. High TSH shows hypothyroidism and low TSH indicates hyperthyroidism. TSH assays are highly sensitive, and the detection of subclinical thyroid dysfunction is a valuable screening tool (Taylor *et al.*, 2018). TSH interpretation in diabetic populations is difficult, however. Poorly controlled diabetes has lower TSH levels, independent of thyroid dysfunction, and this is due to glycemic control on TSH secretion. The occurrence of this phenomenon, which is called non-thyroidal illness syndrome (NTIS), makes it difficult to distinguish between true thyroid dysfunction and transient thyroid changes induced by metabolic stress (Fliers *et al.*, 2021). Furthermore, insulin resistance and hyperinsulinemia, which are common in type 2 diabetes and can alter TSH levels, may have a direct effect on the hypothalamic-pituitary-thyroid (HPT) axis (Elumalai *et al.*, 2024).

3.2. Free T3 and Free T4 Levels

Biologically active forms of thyroid hormones free T3 and free T4 are free. Measuring their levels directly tells you how active your thyroid gland is. Free T4 is the marker of the principal synthetic step of thyroid hormone, whereas free T3 reflects the peripheral conversion of T4 to T3, with this conversion biased by deiodinase enzymes. Together these markers help confirm thyroid dysfunction and distinguish between primary and secondary thyroid disorders (Tanda *et al.*, 2022).

Free T3 levels are important in diabetic populations because of their role in glucose metabolism. The poor control of diabetes is frequently associated with low free T3 levels and increased insulin resistance and cardiovascular risk (Wang *et al.*, 2018). On the other hand, hyperglycemia may be worsened by increases in free T3 due to an enhancement of hepatic gluconeogenesis (Eom *et al.*, 2022). Less affected by glycemic fluctuations, free T4 levels may still fluctuate due to changes in thyroid-binding globulin (TBG) levels, which depend on obesity, insulin resistance, and medication use as shown in Figure 1 (Khan *et al.*, 2021).



Figure 1: Key Biomarkers of Thyroid Dysfunction and Their Interactions

4. Utility and Limitations in Diabetic Populations

Conventional thyroid biomarkers are widely used but poor in diabetic populations. NTIS complicates the interpretation of TSH and free thyroid hormone levels in diabetes because of its high prevalence. Low T3, normal or low T4, and normal or low TSH characterize NTIS, a form of hypothyroidism mimicking true thyroid dysfunction but resulting from an adaptive response to systemic illness. Caution is therefore warranted in the diagnosis of thyroid disorders using conventional biomarkers only (De Luca *et al.*, 2021). Another barrier is the effect of the medications used in diabetes mellitus on thyroid function tests. Metformin, a common drug for type 2 diabetes, has been

demonstrated to lower TSH levels in euthyroid persons with type 2 diabetes. However, this effect may be due to an improvement in insulin sensitivity and metabolic control, but may also mask underlying thyroid dysfunction and delay diagnosis (Haroon *et al.,* 2021). As with other immunosuppressive agents used in diabetic complications, corticosteroids may also suppress TSH secretion, complicating interpretation (Hattersley *et al.,* 2021). However, conventional biomarkers are still essential to monitor thyroid function in diabetic patients. The reliability of these assays has been improved by advances in assay sensitivity and specificity, and their clinical utility has been improved by the development of reference ranges specific to particular populations. Age and sex-specific TSH reference ranges have been established in population-based studies that address variability by demographic factors (Rupani *et al.,* 2023). It also emerges evidence that combining conventional biomarkers with novel ones might increase diagnostic accuracy. For instance, adding oxidative stress and inflammatory indicators like malondialdehyde (MDA) and C-reactive protein (CRP) may improve thyroid function panels' capacity to identify thyroid dysfunction in diabetics (Mancini *et al.,* 2016). Machine learning algorithms and artificial intelligence are also being considered for integrating clinical, biochemical, and genetic data, to perform personalized diagnosis and management (Bini *et al.,* 2021).

5. Emerging Biomarkers and Their Clinical Relevance

The increased understanding of the interplay between thyroid dysfunction and diabetes has motivated the search for novel biomarkers. These new markers are designed to increase diagnostic precision, earlier detection, and a deeper understanding of the pathophysiology of thyroid dysfunction in the diabetic population.

5.1. Thyroglobulin and Thyroid Peroxidase Antibodies

Thyroid autoimmunity is marked by key markers, Thyroglobulin (Tg), and thyroid peroxidase antibodies (TPO-Ab). Tg and TPO-Ab are elevated and strongly associated with autoimmune thyroid disorders like Hashimoto's thyroiditis and Graves' disease. These antibodies are important markers of autoimmune overlap in type 1 diabetes. Recent studies have demonstrated that in diabetic patients, the presence of TPO-Ab is associated with an increased risk of subclinical hypothyroidism and overt thyroid dysfunction, and therefore there is a need for periodic thyroid function monitoring of these populations (Tudor *et al.,* 2020). Thyroglobulin has also been studied as a potential marker of thyroid cancer risk in people with diabetes, but beyond autoimmunity. Given the diabetes-associated metabolic changes such as hyperinsulinemia and chronic inflammation, thyroglobulin secretion may be influenced, and further exploration of its clinical utility is warranted (Pessentheiner *et al.,* 2020).

5.2. Reverse T3

Reverse T3 (rT3), an inactive metabolite of thyroxine (T4), has recently been shown to be a promising marker of thyroid function, especially in nonthyroidal illness syndrome (NTIS). The peripheral metabolism of thyroid hormones is altered in diabetic patients with poor glycemic control and elevated rT3 levels are commonly seen. This elevation may represent a metabolic stress adaptive elevation, conserving energy during periods of illness or dysregulated glucose homeostasis (Halsall *et al.,* 2021). It is suggested that rT3 may be a useful adjunct to conventional markers, especially to distinguish NTIS from true hypothyroidism. Moreover, rT3 levels have been associated with increased cardiovascular risk and insulin resistance, particularly among patients with diabetes, and make a case for using rT3 to stratify diabetic patients according to their metabolic and vascular risk profiles (Xu *et al.,* 2024).

5.3. Cytokines and Inflammatory Markers

Both diabetes and thyroid dysfunction have a hallmark of chronic low-grade inflammation. Interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C reactive protein (CRP) have been investigated as biomarkers of systemic inflammation that may be associated with thyroid dysfunction in diabetic populations. IL-6 and TNFα levels are elevated and suppress thyroid hormone synthesis, impair peripheral hormone conversion, and exacerbate thyroid dysfunction in diabetes (Chauhan *et al.,* 2024). Another acute-phase protein, CRP, has also been linked to thyroid dysfunction in diabetes. Patients with subclinical hypothyroidism have higher CRP levels, which are correlated with insulin resistance, obesity, and poor glycemic control. These findings indicate that CRP may act as a dual-purpose marker for systemic inflammation and thyroid dysfunction in diabetic patients (Ayatollahi *et al.,* 2024).

5.4. Genetic and Epigenetic Markers

New avenues into understanding the interplay between thyroid dysfunction and diabetes have been opened by the identification of genetic and epigenetic markers. Several susceptibility loci as the FOXE1, PAX8, and TSHR genes are also identified in the genetic studies of thyroid hormone synthesis and control. These genes are polymorphisms associated with a higher risk of thyroid dysfunction in diabetic populations, such as type 1 diabetes (Li *et al.,* 2021). Attention has also been paid to epigenetic modifications such as DNA methylation, and microRNA (miRNA) expression. Patients with diabetes and thyroid dysfunction had aberrant methylation of thyroid-specific genes, TPO and DUOX2, that are consistent with epigenetic dysregulation in disease pathogenesis (Stoupa *et al.,* 2016). Moreover, miR-21 and miR-146a have been reported to control inflammation and thyroid autoimmunity and therefore may serve as therapeutic targets (Martínez-Hernández *et al.,* 2023).

Table 1: Emerging Biomarkers for Thyroid Dysfunction in Diabetic Populations: Roles, Relevance, and Associated Evidence

Category	Biomarker	Role and Relevance	References
"Thyroglobulin and Thyroid Peroxidase Antibodies	Thyroglobulin (Tg)	- Elevated in autoimmune thyroid disorders like Hashimoto's thyroiditis and Graves' disease. - Associated with thyroid cancer risk in diabetes due to metabolic changes.	Tudor *et al.*, 2020; Pessentheiner *et al.*, 2020
	Thyroid Peroxidase Antibodies (TPO-Ab)	- Marker of autoimmune overlap in type 1 diabetes. - Associated with increased risk of subclinical hypothyroidism and overt thyroid dysfunction.	Tudor *et al.*, 2020
Reverse T3 (rT3)	Reverse T3 (rT3)	- Inactive metabolite of T4. - Elevated in nonthyroidal illness syndrome (NTIS) in diabetic patients with poor glycemic control. - Associated with cardiovascular risk and insulin resistance.	Halsall *et al.*, 2021; Xu *et al.*, 2024
Cytokines and Inflammatory Markers	Interleukin 6 (IL-6)	- Suppresses thyroid hormone synthesis and impairs peripheral conversion. - Exacerbates thyroid dysfunction in diabetes.	Chauhan *et al.*, 2024
	Tumor Necrosis Factor-alpha (TNF-α)	- Contributes to systemic inflammation. - Impairs thyroid hormone metabolism in diabetic populations.	Chauhan *et al.*, 2024
	C-reactive Protein (CRP)	- Elevated in subclinical hypothyroidism. - Correlates with insulin resistance, obesity, and poor glycemic control. - Dual marker for systemic inflammation and thyroid dysfunction.	Ayatollahi *et al.*, 2024
Genetic and Epigenetic Markers	FOXE1, PAX8, TSHR Genes	- Polymorphisms associated with increased risk of thyroid dysfunction in type 1 diabetes.	Li *et al.*, 2021
	DNA Methylation (TPO, DUOX2)	- Aberrant methylation observed in diabetes and thyroid dysfunction. - Indicates epigenetic dysregulation in disease pathogenesis.	Stoupa *et al.*, 2016
	MicroRNAs (miR-21, miR-146a)	- Regulate inflammation and thyroid autoimmunity. - Potential therapeutic targets.	Martínez-Hernández *et al.*, 2023"

Table 1 summarizes key emerging biomarkers for thyroid dysfunction in diabetic populations, emphasizing their roles, clinical relevance, and supporting evidence. It categorizes biomarkers into autoantibodies (Tg, TPO-Ab), reverse T3, inflammatory markers (IL-6, TNF-α, CRP), and genetic/epigenetic markers (FOXE1, PAX8, TSHR, DNA methylation, microRNAs). Each biomarker is linked to specific mechanisms, such as autoimmune overlap, metabolic regulation, or systemic inflammation, and highlights their potential for improving diagnostic precision and therapeutic strategies.

6. Diagnostic Challenges in Diabetic Populations

Diabetic populations have complex thyroid dysfunction due to the interactions of glycemic control, comorbidities, and polypharmacy. Alterations in thyroid hormone metabolism and the hypothalamic pituitary thyroid (HPT) axis can be induced by poor glycemic control. Peripheral conversion of thyroxine (T4) to triiodothyronine (T3) is impaired by chronic hyperglycemia, leading to increased reverse T3 (rT3) levels and NTIS, a syndrome secondary to hypothyroidism (Wasyluk *et al.*, 2021). Transient suppression of TSH levels by acute glycemic fluctuations, as in diabetic ketoacidosis (DKA), complicates the differentiation between transient and true thyroid dysfunction (Tolcher *et al.*, 2024). Hypoglycemia may further suppress TSH through counter-regulatory hormone responses, and confounding diagnoses (Almalki *et al.*, 2020).

Chronic kidney disease (CKD) and obesity are comorbidities that complicate the diagnosis. TSH clearance and thyroid hormone metabolism are affected in CKD leading to low T3 syndrome (Kaka *et al.*, 2022). Thyroid hormone demand and deiodinase activity are altered by obesity, often with elevated TSH

levels that are misinterpreted as subclinical hypothyroidism. Results can be contextualized by the fact that weight loss can normalize these alterations (Biondi, 2023). Interpretations are further complicated by polypharmacy. Metformin may reduce TSH levels and therefore mask thyroid dysfunction (Palui *et al.,* 2019). Glucocorticoids and SGLT2 inhibitors also affect thyroid function, with different clinical relevance (Bartalena *et al.,* 2018; Kakouri *et al.,* 2021). Amiderone and lithium are also non-diabetes medications that affect thyroid tests greatly and should be evaluated with a thorough medication history (Trohman *et al.,* 2019). Improving diagnostic accuracy involves more than glycemic control and addressing comorbidities and medication effects. New biomarkers such as rT3 and inflammatory markers and new technologies including machine learning have the potential to increase diagnostic precision and outcomes in diabetic populations (Chen *et al.,* 2024).

7. Advances in Analytical Techniques for Biomarker Detection

Recent advances in high-sensitivity assays and omics technologies have detected and quantified biomarkers for thyroid dysfunction in diabetes. They allow more precise and earlier diagnosis, even under conditions of complexity for traditional methods. Measurement of thyroid biomarkers, such as Thyroid-Stimulating Hormone (TSH), free thyroxine (T4), and free triiodothyronine (T3), has been revolutionized by high-sensitivity assays. These assays employ immunoassay techniques including electrochemiluminescence (ECL) and chemiluminescent microparticle immunoassays (CMIA) that provide highly increased analytical sensitivity and specificity. For example, ECL-based assays can measure small fluctuations in TSH levels to pinpoint subclinical thyroid dysfunctions, which are notoriously difficult to identify in diabetic patients (Kumar *et al.,* 2019). In addition, these assays are robust for the detection of low concentrations of thyroid hormones in cases of non-thyroidal illness syndrome (NTIS), a frequent disease in diabetic populations (Ijaz *et al.,* 2024). Beyond traditional immunoassays, omic technologies including proteomics and metabolomics have also proven to be transformative follow-on tools for biomarker discovery and validation. The large-scale study of proteins, their structure, function, and interactions is known as proteomics. Mass spectrometry (MS)--based proteomics advances have enabled the identification of new thyroid-related proteins and post-translational modifications that may be potential biomarkers for thyroid dysfunction in diabetes. The proteomic profile shows dysregulation of thyroid-binding globulin and deiodinase enzymes in diabetic patients and provides new insight into the relationship between glucose metabolism and thyroid function (Che *et al.,* 2024).

In addition to the comprehensive analysis of small molecules (metabolites) in biological systems, metabolomics has provided additional ways to understand thyroid dysfunction. Nuclear magnetic resonance (NMR) spectroscopy and MS-based metabolomic studies have identified unique metabolic signatures associated with thyroid hormone dysregulation (Abooshahab *et al.,* 2019). Changes in lipid and amino acid metabolism are often exacerbated in diabetic patients and these include. As an example, metabolomic profiling has shown that branched-chain amino acids and lipid metabolites are altered in hypothyroid subjects with concomitant diabetes and thus might be potential biomarkers for early diagnosis and monitoring (López-López *et al.,* 2018).

Biomarker discovery also involves critical roles in genomics and epigenomics. With the advent of high throughput sequencing technologies (next-generation sequencing, NGS), genetic variants and epigenetic modifications causally linked to thyroid dysfunction have been identified (Bhattacharya *et al.,* 2023). Diabetic populations have been shown to have altered biomarker levels which are related to specific single nucleotide polymorphisms (SNPs) in genes responsible for thyroid hormone synthesis and metabolism. Furthermore, DNA methylation and histone modification patterns of thyroid-specific genes add to the genetic basis of thyroid dysfunction in diabetes (Lafontaine *et al.,* 2023). However, advances in analytical instrumentation have followed these technological developments. The precise quantification of thyroid biomarkers and the detection of novel metabolites with high accuracy is possible with high-resolution mass spectrometers, such as quadrupole time of flight (QTOF) and orbitrap systems. The combination of liquid chromatography (LC) with MS increases the separation and identification of complex biomolecules and provides enhanced diagnostic capabilities for thyroid dysfunction (Zhang *et al.,* 2021). Additionally, bioinformatics and machine learning (ML) have become essential in analyzing or interpreting large datasets from omics technologies. Biomarkers are correlated and patterned by ML algorithms to develop predictive models of thyroid dysfunction in diabetes. They are based on clinical, biochemical, and demographic data to give personalized diagnostic and prognostic insights (Giorgini *et al.,* 2024).

Table 2: Advances in Analytical Techniques for Biomarker Detection in Thyroid Dysfunction and Diabetes

Analytical Technique	Description	Key Applications	References
High-Sensitivity Assays	Techniques like electrochemiluminescence (ECL) and chemiluminescent microparticle immunoassays (CMIA)	Precise detection of small fluctuations in TSH and low concentrations of thyroid hormones (e.g., NTIS).	Kumar *et al.,* 2019; Ijaz *et al.,* 2024
Proteomics	Study of protein structure, function, and	Identification of thyroid-	Che *et al.,* 2024

	interactions using mass spectrometry (MS).	binding globulin and deiodinase dysregulation as potential biomarkers.	
Metabolomics	Analysis of small molecules using NMR spectroscopy and MS-based methods.	Detection of unique metabolic signatures, such as altered lipid and branched-chain amino acids.	Abooshahab *et al.*, 2019; López-López *et al.*, 2018
Genomics and Epigenomics	High-throughput sequencing (NGS) to identify genetic variants and epigenetic modifications.	Discovery of SNPs and DNA methylation patterns linked to thyroid dysfunction in diabetic populations.	Bhattacharya *et al.*, 2023; Lafontaine *et al.*, 2023
High-Resolution Mass Spectrometry	Advanced MS instruments like QTOF and orbitrap systems, are often coupled with liquid chromatography (LC).	Accurate quantification of thyroid biomarkers and detection of novel metabolites.	Zhang *et al.*, 2021
Bioinformatics and Machine Learning	Computational tools to analyze omics data and develop predictive models.	Correlation of biomarkers and development of personalized diagnostic and prognostic insights.	Giorgini *et al.*, 2024

Table 2 highlights advanced analytical techniques revolutionizing biomarker detection for thyroid dysfunction in diabetes. High-sensitivity assays, such as ECL and CMIA, enable precise detection of thyroid hormones and TSH fluctuations. Proteomics and metabolomics offer insights into protein interactions and metabolic signatures, respectively, while genomics and epigenomics identify genetic variants and epigenetic modifications linked to thyroid dysfunction. High-resolution mass spectrometry enhances biomarker quantification, and bioinformatics with machine learning facilitates predictive modeling for personalized diagnostics.

8. Clinical Implications and Therapeutic Perspectives

Biomarker research integration into clinical practice has important implications for thyroid dysfunction management in diabetic populations. Since thyroid abnormalities can be early detected, they can improve metabolic control, reduce complications, and improve patients' outcomes. Biomarker-guided strategies provide a path to precision medicine and tailored treatments based on individual patient profiles and thyroid and glucose metabolism interplay. The bidirectional relationship between diabetes and thyroid dysfunction dictates early identification of thyroid dysfunction in diabetes. Glycemic variability can worsen thyroid dysfunction, and impaired thyroid hormone metabolism may worsen poor glycemic control in diabetes. Early and more accurate detection is made possible by sensitive biomarkers, such as TSH example and free T4, and emerging markers such as reverse T3 (rT3) and cytokines. For example, timely intervention can reduce cardiovascular risks, and improve insulin sensitivity, given that subclinical hypothyroidism is identified. Thyroid dysfunction is often corrected in diabetes and correction of thyroid hormones often leads to better glycemic control as thyroid hormones affect important processes including glucose absorption, hepatic glucose production, and peripheral glucose uptake (Shpakov, 2017). Management approaches have also been transformed by biomarker-guided therapeutic strategies. Reliable biomarkers make it possible to personalize treatment plans according to specific pathophysiological profiles. As an example, monitoring TSH and inflammatory markers such as CRP in patients with subclinical hypothyroidism allows decisions about levothyroxine therapy. Tracking free T3 and T4 levels in hyperthyroid diabetic patients also helps support the use of antithyroid medication or radioactive iodine therapy without detriment to glucose metabolism (Wolmarans, 2017). More importantly, emerging biomarkers — genetic and epigenetic — allow for the stratification of patients by risk, enabling prevention and targeted interventions. Biomarker insights inform a promising avenue to improve outcomes through personalized medicine. The advances in genomics, proteomics, metabolomics, and genomics have elucidated the mechanisms of disease and inter-individual variability. Therefore, genetic polymorphisms in thyroid hormone receptor genes can predict patient response to a particular treatment or treatment, which allows tailored approaches (Ajayi *et al.*, 2018). Application of Machine learning models using biomarker data can also predict disease progression and optimal therapeutic regimens (Hong *et al.*, 2020) but integrating biomarker-driven approaches, can help in improving diagnostic accuracy, treatment planning, and patient care and pave the way for precision medicine in managing thyroid dysfunction in diabetes.

9. Future Directions

Although much has been learned about thyroid dysfunction in diabetes, and much has been done to manage it, there remain gaps in research and opportunities for innovation. To improve diagnostic accuracy, therapeutic outcomes, and overall patient care it is important to address these gaps. The main challenge is the poor understanding of the intricate interaction of thyroid dysfunction with diabetes at the molecular level. What current biomarkers, like TSH and free thyroid hormones, can teach us is invaluable, but they don't always capture the nuances of thyroid hormone metabolism and immune response in diabetic

patients. There is a need for large-scale, longitudinal studies that investigate the dynamic changes in thyroid biomarkers across different stages of diabetes and in diverse patient populations. Future studies would better understand more specific and sensitive biomarkers of early and advanced stages of thyroid dysfunction. Biomarker research is a transformative opportunity when we integrate artificial intelligence (AI) and big data analytics. Large datasets can be analyzed by machine learning algorithms to find correlations and patterns that are incomprehensible to humans. AI can combine clinical, biochemical, genetic, and epigenetic data to unveil novel biomarkers and to more accurately forecast the progression of disease. Predictive models can also be constructed that predict the risk for thyroid dysfunction in diabetic patients, permitting proactive interventions. In addition, AI-powered tools can enable the design and optimization of personalized treatment plans with targeted decision-making about therapeutic elements based on patient profiles. Novel biomarkers also promise to address current limitations and to develop and validate them. Through the emerging fields of proteomics and metabolomics, unique molecular signatures of thyroid dysfunction in diabetes may be identified. Cytokines and inflammatory markers are currently being examined as potentially indicative of the autoimmune and inflammatory processes that underlie thyroid dysfunction. Moreover, further development in genetic and epigenetic research could turn up certain genetic or methylation mutations that increase the risk for thyroid disturbance in individuals. While these findings translate into clinically viable tests, robust validation studies for robust validation studies are essential, standardization of methodologies is required, and integration into existing diagnostic frameworks is necessary.

10. Conclusion

The connection between thyroid disease and diabetes is complicated, and thus a comprehensive approach to diagnosis management, and treatment of thyroid dysfunction in diabetes is indicated. Glucose metabolism involves thyroid hormones, and their dysregulation can worsen diabetic conditions, as diabetes worsens thyroid function. The importance of thyroxine dysfunction early detection and precise monitoring in diabetic populations is underlined by this bidirectional interaction. Although conventional biomarkers such as TSH, free T3, and free T4 are still the mainstay of thyroid dysfunction diagnosis, interpretation of these biomarkers can be complicated by factors such as glycemic control, comorbidities, and polypharmacy in diabetic patients. Promising ways to improve diagnostic precision are emerging biomarkers, including reverse T3, cytokines, and genetic and epigenetic markers. Analytical techniques such as high-sensitivity assays and omics technologies have improved our ability to identify subtle changes in thyroid hormone metabolism and discover novel biomarkers. However, there are still many research gaps. A better understanding of dynamic changes in thyroid function biomarkers across stages of diabetes requires the development of large-scale, longitudinal studies. In addition, the combination of artificial intelligence and big data analytics has great potential for biomarker discovery to develop predictive models and personalized therapeutic strategies. The convergence of advanced diagnostic tools, biomarker-guided therapeutic approaches, and personalized medicine will be the future of thyroid dysfunction management in diabetes. These innovations leverage, and in turn, clinicians can optimize patient care, reduce complications, and improve outcomes. These goals will require continued research and collaboration between endocrinologists, diabetologists, and researchers to learn about and treat these intertwined conditions.

11. References

1. Abooshahab, R., Gholami, M., Sanoie, M., Azizi, F., & Hedayati, M. (2019). Advances in metabolomics of thyroid cancer diagnosis and metabolic regulation. Endocrine, 65, 1-14.
2. Ajayi, A. F., Adebayo, E. T., Adebayo, I. O., Oyekunle, O. S., Amos, V. O., Bamidele, S. E., & Olatinwo, G. O. (2018). Application of Data Science Approaches to Investigate Autoimmune Thyroid Disease in Precision Medicine. Hypothyroidism-New Aspects of an Old Disease.
3. Al-bayati, A., & Al-Khateeb, S. (2021). The effects of thyroid hormones and their abnormalities on intestinal and hepatic glucose metabolism. Sch. Int. J. Biochem, 4, 26-36.
4. Ayatollahi, A., Moosavi, Z., & Ayatollahi, H. (2024). Serum C-reactive Protein Levels about Insulin Resistance and Beta Cell Function in Iranian Women with Subclinical Hypothyroidism. *Iranian Journal of Pathology*, *19*(3), 326.
5. Bartalena, L., Bogazzi, F., Chiovato, L., Hubalewska-Dydejczyk, A., Links, T. P., & Vanderpump, M. (2018). 2018 European Thyroid Association (ETA) guidelines for the management of amiodarone-associated thyroid dysfunction. European Thyroid Journal, 7(2), 55-66.
6. Bhattacharya, S., Mahato, R. K., Singh, S., Bhatti, G. K., Mastana, S. S., & Bhatti, J. S. (2023). Advances and challenges in thyroid cancer: The interplay of genetic modulators, targeted therapies, and AI-driven approaches. Life Sciences, 122110.
7. Bini, F., Pica, A., Azzimonti, L., Giusti, A., Ruinelli, L., Marinozzi, F., & Trimboli, P. (2021). Artificial intelligence in thyroid field—a comprehensive review. Cancers, 13(19), 4740.
8. Biondi, B. (2023). Subclinical hypothyroidism in patients with obesity and metabolic syndrome: a narrative review. Nutrients, 16(1), 87.
9. Biondi, B., Kahaly, G. J., & Robertson, R. P. (2019). Thyroid dysfunction and diabetes mellitus: two closely associated disorders. Endocrine Reviews, 40(3), 789-824.
10. Brawerman, G. M., Kereliuk, S. M., Brar, N., Cole, L. K., Seshadri, N., Pereira, T. J., ... & Dolinsky, V. W. (2019). Maternal resveratrol administration protects against gestational diabetes-induced glucose intolerance and islet dysfunction in the rat

offspring. The Journal of Physiology, 597(16), 4175-4192.
11. Chauhan, A., & Patel, S. S. (2024). Thyroid Hormone and Diabetes Mellitus Interplay: Making Management of Comorbid Disorders Complicated. Hormone and Metabolic Research.
12. Che, Y., Zhao, M., Gao, Y., Zhang, Z., & Zhang, X. (2024). Application of machine learning for mass spectrometry-based multi-omics in thyroid diseases. Frontiers in Molecular Biosciences, 11, 1483326.
13. Chen, C., Xie, Z., Shen, Y., & Xia, S. F. (2018). The roles of thyroid and thyroid hormone in pancreas: physiology and pathology. International journal of endocrinology, 2018(1), 2861034.
14. Chen, S., Yu, M., Yao, Y., Li, Y., He, A., Zhou, Z., ... & Sun, H. (2024). Thyroid hormone biomonitoring: A review on their metabolism and machine-learning based analysis on effects of endocrine disrupting chemicals. Environment & Health, 2(6), 350-372.
15. Cicatiello, A. G., Di Girolamo, D., & Dentice, M. (2018). Metabolic effects of the intracellular regulation of thyroid hormone: old players, new concepts. Frontiers in endocrinology, 9, 474.
16. De Luca, R., Davis, P. J., Lin, H. Y., Gionfra, F., Percario, Z. A., Affabris, E., ... & Incerpi, S. (2021). Thyroid hormones interact with immune response, inflammation, and non-thyroidal illness syndrome. Frontiers in cell and developmental biology, 8, 614030.
17. Elumalai, V., Mahadevan, Y., Balasubramanium, S., Anton, M. C., Jyothirmayi, B., & Sridevi, C. (2024). Evaluation of thyroid status in type 2 Diabetes Mellitus concerning insulin Resistance. Biomedical and Pharmacology Journal, 17(4), 2575-2584.
18. Eom, Y. S., Wilson, J. R., & Bernet, V. J. (2022). Links between thyroid disorders and glucose homeostasis. Diabetes & Metabolism Journal, 46(2), 239.
19. Fliers, E., & Boelen, A. (2021). An update on non-thyroidal illness syndrome. Journal of Endocrinological Investigation, 44(8), 1597-1607.
20. Fröhlich, E., & Wahl, R. (2017). Thyroid autoimmunity: role of anti-thyroid antibodies in thyroid and extra-thyroidal diseases. Frontiers in immunology, 8, 521.
21. Frommer, L., & Kahaly, G. J. (2021). Type 1 diabetes and autoimmune thyroid disease—the genetic link. Frontiers in endocrinology, 12, 618213.
22. Giorgini, F., Di Dalmazi, G., & Diciotti, S. (2024). Artificial intelligence in endocrinology: a comprehensive review. Journal of Endocrinological Investigation, 47(5), 1067-1082.
23. Halsall, D. J., & Oddy, S. (2021). Clinical and laboratory aspects of 3, 3′, 5′-triiodothyronine (reverse T3). Annals of clinical biochemistry, 58(1), 29-37.
24. Haroon, S. M., Khan, K., Maqsood, M., Iqbal, S., Aleem, M., & Khan, T. U. (2021). Exploring the effect of metformin to lower thyroid-stimulating hormone in euthyroid and hypothyroid type-2 diabetic patients. Cureus, 13(2).
25. Hattersley, R., Nana, M., & Lansdown, A. J. (2021). Endocrine complications of immunotherapies: a review. Clinical Medicine, 21(2), e212-e222.
26. Hong, N., Park, H., & Rhee, Y. (2020). Machine learning applications in endocrinology and metabolism research: an overview. Endocrinology and metabolism, 35(1), 71-84.
27. Ijaz, A., Anjum, M. U., Ahmed, F., Piracha, S. N., Habib, F., Shaukat, M. B., ... & Qureshi, N. (2024). Establishment of Reference Values of Markers of Non-Thyroidal Illness Syndrome on a State-of-the-Art Fully Automated ABei-based chemiluminescence System. medRxiv, 2024-06.
28. Kaka, N., Sethi, Y., Patel, N., Kaiwan, O., Al-Inaya, Y., Manchanda, K., & Uniyal, N. (2022). Endocrine manifestations of chronic kidney disease and their evolving management: A systematic review. Disease-a-Month, 68(12), 101466.
29. Kakouri, A., Kanti, G., Kapantais, E., Kokkinos, A., Lanaras, L., Farajian, P., ... & Valsamakis, G. (2021). New incretin combination treatments under investigation in obesity and metabolism: a systematic review. Pharmaceuticals, 14(9), 869.
30. Kalra, S., Aggarwal, S., & Khandelwal, D. (2019). Thyroid dysfunction and type 2 diabetes mellitus: screening strategies and implications for management. Diabetes Therapy, 10(6), 2035-2044.
31. Khan, Y. H., Saifullah, A., Mallhi, T. H., Bukhsh, A., & Khan, T. M. (2021). Impaired Thyroid function in metabolic disorders. Endocrine Disrupting Chemicals-induced Metabolic Disorders and Treatment Strategies, 95-110.
32. Kim, H. K., & Song, J. (2022). Hypothyroidism and diabetes-related dementia: Focused on neuronal dysfunction, insulin resistance, and dyslipidemia. International Journal of Molecular Sciences, 23(6), 2982.
33. Kumar, K., Mishra, S. K., Dwivedi, P., & Sumana, G. (2019). Recent progress in the sensing techniques for the detection of human thyroid stimulating hormone. TrAC Trends in Analytical Chemistry, 118, 666-676.
34. Lafontaine, N., Wilson, S. G., & Walsh, J. P. (2023). DNA methylation in autoimmune thyroid disease. The Journal of Clinical Endocrinology & Metabolism, 108(3), 604-613.
35. Li, L., Jia, C., Li, X., Wang, F., Wang, Y., Chen, Y., ... & Zhao, D. (2021). Molecular and clinical characteristics of congenital hypothyroidism in a large cohort study based on comprehensive thyroid transcription factor mutation screening in Henan. *Clinica Chimica Acta*, *518*, 162-169.
36. López-López, Á., López-Gonzálvez, Á., Barker-Tejeda, T. C., & Barbas, C. (2018). A review of validated biomarkers obtained through metabolomics. Expert review of molecular diagnostics, 18(6), 557-575.
37. Macvanin, M. T., Gluvic, Z., Zafirovic, S., Gao, X., Essack, M., & Isenovic, E. R. (2023). The

protective role of nutritional antioxidants against oxidative stress in thyroid disorders. Frontiers in endocrinology, 13, 1092837.
38. Mancini, A., Di Segni, C., Raimondo, S., Olivieri, G., Silvestrini, A., Meucci, E., & Currò, D. (2016). Thyroid hormones, oxidative stress, and inflammation. Mediators of inflammation, 2016(1), 6757154.
39. Martínez-Hernández, R., & Marazuela, M. (2023). MicroRNAs in autoimmune thyroid diseases and their role as biomarkers. Best Practice & Research Clinical Endocrinology & Metabolism, 37(2), 101741.
40. Palui, R., Sahoo, J., Kamalanathan, S., Kar, S. S., Sridharan, K., Durgia, H., ... & Patil, M. (2019). Effect of metformin on thyroid function tests in patients with subclinical hypothyroidism: an open-label randomized controlled trial. Journal of Endocrinological Investigation, 42, 1451-1458.
41. Pessentheiner, A. R., Ducasa, G. M., & Gordts, P. L. (2020). Proteoglycans in obesity-associated metabolic dysfunction and meta-inflammation. Frontiers in immunology, 11, 769.
42. Rupani, S. V., & Kotwal, A. (2023). Age-and Sex-Specific Reference Ranges for Thyroid Function Tests Reduce Misdiagnosis of Subclinical Thyroid Dysfunction. *Clinical Thyroidology*, *35*(4), 131-134.
43. Sabatino, L., Vassalle, C., Del Seppia, C., & Iervasi, G. (2021). Deiodinases and the three types of thyroid hormone deiodination reactions. Endocrinology and Metabolism, 36(5), 952-964.
44. Sakr, M. F., & Sakr, M. F. (2020). Hashimoto's disease. Thyroid Disease: Challenges and Debates, 71-132.
45. Shpakov, A. O. (2017). Pharmacological approaches for correction of thyroid dysfunctions in diabetes mellitus. Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry, 11, 349-362.
46. Stoupa, A., Kariyawasam, D., Carré, A., & Polak, M. (2016). Update of thyroid developmental genes. Endocrinology and Metabolism Clinics, 45(2), 243-254.
47. Tanda, M. L., & Ippolito, S. (2022). Thyroid Hormone Receptors. In Endocrine Pathology (pp. 788-791). Cham: Springer International Publishing.
48. Taylor, P. N., Albrecht, D., Scholz, A., Gutierrez-Buey, G., Lazarus, J. H., Dayan, C. M., & Okosieme, O. E. (2018). Global epidemiology of hyperthyroidism and hypothyroidism. Nature Reviews Endocrinology, 14(5), 301-316.
49. Teixeira, P. D. F. D. S., Dos Santos, P. B., & Pazos-Moura, C. C. (2020). The role of thyroid hormone in metabolism and metabolic syndrome. Therapeutic advances in endocrinology and metabolism, 11, 2042018820917869.
50. Tolcher, M. C., Hoff, H. S., Aagaard, K. M., & Phelan, J. P. (2024). Endocrine Emergencies. Critical Care Obstetrics, 541-553.
51. Tomer, Y. (2014). Mechanisms of autoimmune thyroid diseases: from genetics to epigenetics. Annual Review of Pathology: Mechanisms of Disease, 9(1), 147-156.
52. Torres, E. M., & Tellechea, M. L. (2025). Biomarkers of endothelial dysfunction and cytokine levels in hypothyroidism: a series of meta-analyses. Expert Review of Endocrinology & Metabolism, (just-accepted).
53. Trohman, R. G., Sharma, P. S., McAninch, E. A., & Bianco, A. C. (2019). Amiodarone and thyroid physiology, pathophysiology, diagnosis and management. Trends in cardiovascular medicine, 29(5), 285-295.
54. Tudor, R. M., Garrahy, A., Woods, C. P., Crowley, R. K., Tormey, W. T., Smith, D., ... & Thompson, C. J. (2020). The prevalence and incidence of thyroid dysfunction in patients with diabetes-a longitudinal follow-up study. Irish Journal of Medical Science (1971-), 189, 171-175.
55. Walczak, K., & Sieminska, L. (2021). Obesity and thyroid axis. International journal of environmental research and public health, 18(18), 9434.
56. Wang, C. Y., Yu, T. Y., Shih, S. R., Huang, K. C., & Chang, T. C. (2018). Low total and free triiodothyronine levels are associated with insulin resistance in non-diabetic individuals. Scientific reports, 8(1), 10685.
57. Wasyluk, W., Wasyluk, M., & Zwolak, A. (2021). Sepsis as a pan-endocrine illness—endocrine disorders in septic patients. Journal of Clinical Medicine, 10(10), 2075.
58. Wolmarans, D. W. (2017). Maintaining euthyroidism: fundamentals of thyroid hormone physiology, iodine metabolism and hypothyroidism. South African Family Practice, 59(4), 11-21.
59. Xu, C., Wen, S., Xu, Z., Dong, M., Yuan, Y., Li, Y., & Zhou, L. (2024). Low T3 Syndrome is Associated with Imbalance of Bone Turnover Biomarker in Patients with Type 2 Diabetes. Diabetes, Metabolic Syndrome and Obesity, 3667-3682.
60. Yang, W., Jin, C., Wang, H., Lai, Y., Li, J., & Shan, Z. (2023). Subclinical hypothyroidism increases insulin resistance in normoglycemic people. *Frontiers in Endocrinology*, *14*, 1106968.
61. Yang, W., Jin, C., Wang, H., Lai, Y., Li, J., & Shan, Z. (2023). Subclinical hypothyroidism increases insulin resistance in normoglycemic people. Frontiers in Endocrinology, 14, 1106968.
62. Zhang, J., Wen, X., Li, Y., Li, X., Qian, C., Tian, Y., ... & Duan, Y. (2021). Diagnostic approach to thyroid cancer based on amino acid metabolomics in saliva by ultra-performance liquid chromatography with high-resolution mass spectrometry. Talanta, 235, 122729.